Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Erythropoiesis-stimulating agents (ESAs) remain a cornerstone of anemia management in chronic kidney disease (CKD). However, some patients show an inadequate hemoglobin response despite appropriate or increasing ESA exposure. ESA hyporesponsiveness is clinically important because persistent dose escalation may provide limited benefit while increasing treatment burden and potential cardiovascular and thrombotic risk.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
